Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

DAOSD may follow the course of a chronic illness. Long-term corticosteroid eyedrops were required in many patients and when taper was possible, this was done after a prolonged treatment duration. Most patients' ocular symptoms could be controlled, allowing dupilumab continuation.